Nation

Revolutionizing Diagnostics: Hong Kong's Phase Scientific Secures $34 Million to Transform Urine Testing

2025-05-21

Author: Kai

Hong Kong's Phase Scientific Lands Massive Funding for Urine-Based Innovations

In a groundbreaking move for the biotech world, Hong Kong’s Phase Scientific International has successfully raised $34 million in a Series A funding round, marking the largest Series A investment in Asia's diagnostic technology sector since 2019. This impressive feat underscores strong investor confidence in the startup’s pioneering PHASIFY™ technology and its ambitious growth plans.

Backed by Major Investors

The funding is spearheaded by a private equity fund from Value Partners Group, one of Asia's top independent asset management firms, alongside a host of new healthcare-focused investors and continued support from existing global backers.

A Game-Changer in Liquid Biopsy Diagnostics

At the core of Phase Scientific’s offering is its patented PHASIFY™ urine concentration technology, capable of capturing over ten times more biomarkers than the industry's current gold standards. This positions them as the only entity advancing a comprehensive pipeline of urine-based liquid biopsy diagnostics.

Empowering Health Management with Non-Invasive Tests

The company is set to revolutionize healthcare with a range of non-invasive tests aimed at the early detection of cancers, women’s health conditions, and infectious diseases. In a monumental shift from traditional invasive methods, PHASIFY™ facilitates at-home sample collection, paving the way for proactive health management and preventive care.

Path-Breaking Achievements in HPV Testing

Phase Scientific has already made waves with the world’s first urine-based HPV test, achieving substantial clinical validation and gaining international acclaim. A recent collaboration with Peking University Shenzhen Hospital revealed an impressive 93.4% sensitivity in detecting CIN2+ lesions—including precancer and cancer—alongside over 97% concordance with a leading physician-collected test for HPV types 16 and 18.

The Future of Diagnostics Is Here

With this robust funding and groundbreaking technology, Phase Scientific is poised to change the landscape of diagnostic testing, making health management more accessible, convenient, and effective for populations worldwide. Stay tuned as this innovative startup continues to make headlines!